|1.||Domingo, Pere: 7 articles (01/2014 - 07/2004)|
|2.||Cherry, Catherine L: 6 articles (04/2011 - 03/2005)|
|3.||Law, Matthew: 5 articles (01/2014 - 05/2002)|
|4.||Vidal, Francesc: 5 articles (06/2013 - 04/2010)|
|5.||van Griensven, Johan: 5 articles (01/2013 - 06/2009)|
|6.||Ribera, Esteban: 5 articles (01/2013 - 08/2003)|
|7.||Capeau, Jacqueline: 5 articles (02/2012 - 05/2002)|
|8.||Sungkanuparph, Somnuek: 5 articles (02/2010 - 09/2005)|
|9.||Ruxrungtham, Kiat: 5 articles (10/2009 - 06/2004)|
|10.||Manfredi, Roberto: 5 articles (09/2009 - 12/2004)|
|1.||HIV Infections (HIV Infection)
08/01/1995 - "Stavudine appears to hold promise for the treatment of HIV infection in children. "
01/01/2002 - "The efficacy (reduction in viral load and increase in CD4+ lymphocyte counts from baseline) of stavudine once daily-containing triple therapy was similar to that of stavudine immediate release (IR)-containing triple therapy in the treatment of antiretroviral-naive patients with HIV infection in two 48-week, randomised, double-blind trials. "
11/01/1999 - "Stavudine has also been beneficial as part of combination regimens in antiretroviral-experienced patients and children with HIV infection, although data are limited and more studies are needed. "
09/01/1998 - "The results of this study indicate that (i) ingestion of food does not affect the bioavailability of d4T and that patients with HIV infection can take it without regard to meals, and (ii) absorption is essentially complete within 1 h when d4T is administered in the fasted state."
09/01/1996 - "A 6-month study of 8 children with advanced HIV infection shows that combination therapy with d4T and ddI is safe and well tolerated. "
01/01/2015 - "To compare the safety and virologic efficacy of low dose versus high dose stavudine for treating HIV-1 infection. "
01/01/2007 - "We conclude that a regimen of NVP with ddI and d4T provided durable suppression of plasma viral load in HIV-infected patients, with significant improvement in the CD4 cell count, and can be well tolerated by patients with HIV-1 infection."
04/01/2004 - "The authors observed a statistically significant reduction in the rate of viral replication for stavudine added 24 h prior to infection univariate analysis of variance ([UANOVA], t = 2.55, df = 17, P =.021). "
01/01/1990 - "Other studies with the more chronic SIV infection model, however, failed to show any prophylactic efficacy of CS-87, AZT, D4T, or FDT."
05/01/2010 - "Our findings raise the possibility that the incidence of DSP may be reduced with avoidance of stavudine-containing regimens in older subjects, especially with a history of prior TB infection."
|3.||Acquired Immunodeficiency Syndrome (AIDS)
09/01/2011 - "Three months of stavudine-based antiretroviral therapy reduces the severity of distal symmetrical neuropathy in HIV/AIDS patients, but more studies are needed to evaluate the long-term neuropathic effect of stavudine on Africans."
01/01/2015 - "The comprehensive search strategy developed by the Cochrane HIV/AIDS Review Group was used to identify randomised controlled trials that compared the use of low dose versus high dose stavudine. "
04/01/2011 - "HIV-positive Black South Africans (n=395) who had received stavudine for at least six months were recruited at the Virology Clinic of the Charlotte Maxeke Academic Johannesburg Hospital, South Africa, and screened for neuropathy using the AIDS Clinical Trials Group neuropathy screening tool. "
12/15/2004 - "Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332."
01/01/2014 - "Alongside expected risk factors, stavudine use was associated with AIDS [adjusted HR of 1.08 (0.90-1.30)] and death (adjusted HR of 1.60 [1.21-2.11]). "
09/10/1999 - "Five out of 12 patients had a major or mild improvement in their lipodystrophy after stavudine was discontinued. "
02/01/2015 - "Most pediatric lipodystrophy data come from high-income/middle-income countries, but most HIV-infected children live in sub-Saharan Africa, where lipodystrophy studies have predominantly investigated stavudine-based regimens. "
01/01/2015 - "In most studies, lipodystrophy developed after the first six months of therapy, particularly with the use of stavudine. "
10/01/2014 - "This study confirms the association between stavudine and lipodystrophy particulary lipoatrophy and shows that a longer duration of ART was associated with the presence of diabetes. "
06/01/2009 - "All adult patients on stavudine-containing first-line regimens who developed lipoatrophy (diagnosed using a lipodystrophy case definition study-based questionnaire) and whose treatment regimen was changed were included (n=114). "
01/01/2000 - "After discontinuation of stavudine treatment, lactic acidosis improved in 4 patients after 4-60 weeks, and 1 patient died. "
01/01/2014 - "Given that the clinical sequelae of undiagnosed lactic acidosis are either death or at best ART default, this provides further vindication for the decision to phase out stavudine in Malawi."
01/01/2014 - "Lactic acidosis is one of the most serious side effects associated with ART, most commonly associated with stavudine. "
01/01/2012 - "Out of 2581 adults initiating a D4T-containing regimen, D4T was replaced in 276 (10.7%) patients for neuropathy, 14 (0.5%) for lactic acidosis and 957 (37.1%) for lipoatrophy. "
04/01/2011 - "Lactic acidosis associated with severe neuromuscular weakness and stavudine therapy."
|1.||Highly Active Antiretroviral Therapy (HAART)
|4.||Drug Therapy (Chemotherapy)